膀胱癌患者尿中可溶性Fas和可溶性FasL表达水平的意义

 目的　探讨可溶性Fas(sFas)和可溶性FasL(sFasL)在膀胱癌病人尿中的表达及其临床意义。方法　应用双抗体夹心ELISA法检测 4 3例膀胱癌病人术前、术后和 12例正常人尿中sFas和sFasL的表达水平。结果　膀胱癌病人尿sFas和sFasL水平均高于正常对照组 ,sFas与肿瘤临床分期、病理分级正相关 ,sFasL仅与肿瘤临床分期正相关。肿瘤切除术后sFas和sFasL水平均降低 ,而且复发者术后sFas水平显著高于无复发者。结论　sFas和sFasL参与膀胱癌的发生、发展 ,在一定程度上可以反映膀胱癌生物学行为。

Clinical Value of Urine Soluble Fas and Soluble Fas Ligand in Bladder Cancer

Objective To examine the level of soluble Fas (sFas) and soluble Fas ligand (sFasL) in urine of patients with bladder cancer and to investigate their clinical value.Methods Enzyme linked immunosorbent assays (ELISA) was available to detect the level of sFas and sFasL in urine of 43 patients with bladder cancer and 12 cases of normal control.Results The urine level of sFas and sFasL in bladder cancer were significantly higher than those in normal control,respectively. Level of sFas was positive associationwith tumor stage and grade,while level of sFasL was positive association with tumor stage only. Levels of sFas and sFasL were significantly decreased after operation. The level of sFas was higher in recur patients after operation than that in no-recur patients.Conclusion sFas and sFasL play important roles in development and progress of bladder cancer. They may serve as markers for biological behaviors of bladder cancer.